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Thesis Abstract

Epidemiological studies suggest that arsenic exposure is associated with various
detrimental pregnancy outcomes. However, the mechanism for arsenic effects on
pregnancy is unknown. We hypothesize that one of the reproductive outcomes,
miscarriage, resulting from arsenic exposure may be due to placentation defects of
pregnant mice, induced by endothelial vascular defects. The purpose of this study is to 1.
Determine how arsenic exposure in drinking water affects fecundity, placentation and
vascular morphogenesis in vivo. 2. Determine how arsenic exposure affects the balance
between proliferation and apoptosis of bovine endothelial cells (BAE). The data show
that the miscarriage rate is dramatically increased in pregnant mice exposed to arsenic in
drinking water at concentration of 20 ppm (260 jjM) (52.6%), 37.5 ppm (0.49 mM)
(61.0%) and 75 ppm (0.98 mM) (69.7%) compared to control (28%). The miscarriage
rate of 37.5 ppm arsenic exposure group increases from 43% at E7.5 to 60% at E12.5.
The vascular abnormalities of placentas and embryos at El2.5 stage are examined with
bandeiraea simplicifolia lectin I isolectin B4 (BSL-B4) staining. There is significant
decrease in the vasculature of sodium arsenite (Asm) treated placentas (52.0%). In vitro,
we find a dose-dependent inhibition of cell growth and viability, and increased apoptosis
by arsenic treatment for 24 hours on both confluent and non-confluent BAE cells. These
data additionally suggest that confluent cells are more susceptible than proliferating cells
to arsenic toxicity. However, proliferating cells are more susceptible in a loss of
proliferation than confluent cells at doses of 5 pM and 10 jxM arsenic. In conclusion, the
data suggest that arsenic exposure through drinking water in mice does not substantially
affect litter size or pup weight, but does cause spontaneous abortion of the entire litter
between E7.5 and El2.5, which finally results in increased miscarriage rate of pregnant
mice exposed to 37.5 ppm arsenic. The effects may be due in part to abnormal placenta
neovascularization of pregnant mice after arsenic exposure.
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INTRODUCTION

Arsenic is an omnipresent metalloid element naturally occurring in the environment in
the earth's crust. It can be released into ground water and soil by both natural processes
and human extractive activity. It also exists in pesticide and wood preservatives,
pigments and glass (Waugh, 1982). Arsenic has organic and inorganic forms. There are
two oxidation-states of inorganic arsenic: Arsenite (As111) and arsenate (Asv). These two
forms speciate in the environment depending upon the level of dissolved oxygen.
However, arsenate can be converted to arsenite in vivo (Abernathy et al., 1999) and it can
be methylated by microbes to MMA (monomethylarsonic acid) and DMA
(dimethylarsinic acid) (Vahter et al., 2001). This process is traditionally regarded as
detoxification pathway because of less acute toxicity of organic arsenic, but a recent
study suggests this may not be the case (Tonner-Navarro, 1998). Sodium arsenite (As111)
was used throughout this project. The main source of human exposure to this toxicant is
contaminated drinking water and some foods, such as rice, grains and fish (ACSH, 2002).
Higher levels of arsenic contamination in drinking water from several hundred ppb to
over 1 ppm have been observed in Argentina, Bangladesh, Chile, India, Mexico, Thailand
and Taiwan (ACSH, 2002). In this country, some states, including Montana, New
Mexico, Arizona, Nevada, Utah, Southern California, Idaho and Nebraska, have 50 ppb100 ppb of arsenic in drinking water; higher than the currently approved 10 ppb MCL
(maximum contaminant level) (ACSH, 2002).
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Human epidemiological data suggest an association between arsenic exposure in
drinking water and adverse reproductive outcomes. Basically, they can be concluded into
four main aspects.
1. Spontaneous abortion. In 1989, it was reported that a 1.2-fold increased
spontaneous abortion (95 % confidence interval: 1.0-1.6) was found in a community of
286 women living with low levels of arsenic in drinking water (0.8-1.3 ppb) and a 1.7fold increased spontaneous abortion (95 % confidence interval: 0.7-4.2) was found in a
community with high levels of arsenic (1.4-1.9 ppb) (Aschengrau et al., 1989). A study
from Chile showed that higher incidence of late fetal mortality (rate ration (RR) = 1.7;
95% confidence interval (CI), 1.5-1.9), neonatal mortality (RR = 1.52; CI, 1.4-1.7) and
postneonatal mortality (RR = 1.26; CI, 1.2- 1.3) was associated with higher concentration
of arsenic in drinking water (up to 860 ppb) compared to a control community (< 5ppb)
(Hopenhanyn-Rich et al., 2000).
2. Stillbirth. Borzsonyi et al. (1992) reported the potential risk of stillbirth
resulted from arsenic in drinking water in southern Hungary. Another study group in
Bangladesh found the rate of stillbirth (p< 0.046), spontaneous abortion (p< 0.008) and
preterm birth rate (p< 0.018) significantly increased in the arsenic exposed group in
drinking water (>0.1 ppm) comparing with lower level arsenic exposure group (<0.02
ppm) (Ahmad et al., 2001).
3- Preterm birth rate. A report from Taiwan suggested that there was a higher
preterm birth rate (3.74 %) in a group with arsenic exposure in drinking water (from 0.9
ppb up to 3.59 ppm) vs 3.43 % in a control group (<0.9 ppb) (with an odds ratio of 1.10).
They also found that the babies' birth weight in an exposed group was on average 30 g
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(95 % CI= 13.55- 44.55; P=0.002) lighter than those in a control group (Yang et al.,
2003).
4 Birth weight. An epidemiologic study in 2003 from Chile suggested an average
reduction of average birth weight (-57 g; 95% confidence interval = -123 to 9) was
associated with higher level of arsenic in drinking water (42 ppb) compared to control
community (<1 ppb) (Hopenhayn et al., 2003).
These epidemiologic studies were limited by methodological concerns. Human data are
too complicated for interpretation because there are multiple chemicals (copper, barium,
fluoride etc) in drinking water and lifestyle factors could not be excluded. It is also
difficult to determine chronic exposure levels in individuals to correlate the doseresponse effects for arsenic exposure.
There are many experimental animal studies demonstrating arsenic as developmental
toxicant, though the dosages of most of them are intravenous (i.v) or intraperitoneal (i.p)
injection (Holson et al., 2000; Hood, 1978; Hood, 1972). These administration routes
have made it difficult to assess the risk potential of arsenic on human health. Very few
studies have examined the direct toxicity of arsenic exposure in drinking water on
fecundity of pregnant mice, and none of them designed a dose-response study to
determine the lowest concentration of As111 to cause toxicity in developing mice.
Although both these human and experimental studies suggested an association between
arsenic exposures in drinking water with detrimental pregnancy outcomes, it is not clear
why this happens. Both the nutrition and toxicant are transferred to the developing
embryo through the abundant placental vasculature. Inorganic arsenic of both oxidation
states can easily cross the placenta as a low weight molecule (Desesso et al., 1998;

3

Dencker 1983; Lindgren 1984). Eastman first discovered that arsenic is accumulated in
human placenta (Eastman, 1931; Desesso et al., 1998). Concha et al. (1998) found that
arsenic in exposed maternal placenta was 34 |xg/kg, which was almost 5-fold higher than
control women (7 |xg/kg) and most of the arsenic was in DMA (dimethylarsinic acid)
form in the blood plasma of both mother and newborns. In terms of the mechanisms for
fetal and embryonic arsenic toxicity, Hopenhayn et al. (2003) suggested that arsenic
might have vascular effects and cause placental abnormalities or decreased blood flow,
which then retard fetal growth. Further research is needed to provide a better
understanding of the mechanisms for arsenic-induced developmental anomalies.
Based on the current information, we hypothesize that arsenite toxicity impairs vascular
development, causing abnormal placental neovascularization of pregnant mice that
subsequently causes miscarriage. One purpose of this study is to determine how arsenic
exposure affects fecundity, placentation and vascular morphogenesis in pregnant mice.
Endothelial cells are the innermost lining of blood vessels that form the vascular
network. They are the major places where nutrients and toxicants enter the blood vessel.
They are also the frontier targets of toxicants on vascular networks, and the function of
endothelial cells is the foundation of a functional and homeostatic vasculature. The
balance between endothelial cell proliferation and apoptosis, resulting in the viability of
endothelial cells, directly controls vascular differentiation and angiogenesis. We
hypothesize that arsenite toxicity impairs vascular development causing an inadequate
perfusion of tissues that subsequently causes miscarriage. To better understand the
toxicity of arsenic on the vasculature, it is very important to study the effect of arsenic on
endothelial cells. In embryonic life, endothelial cells actively proliferate and differentiate.
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The apoptosis of endothelial cells can severely destroy vasculogenesis in embryo
development and placenta and cord development, leading to serious hemorrhage, finally
causing embryo death (Dimmeler et al., 2000). In contrast, in adult life endothelial cells
are typically quiescent and turn over slowly, similar to the situation for confluent cells in
culture. The apoptosis of endothelial cells in adult neovasculature can regulate the adult
angiogenesis to avoid excess angiogenesis (Dimmeler et al., 2000). The differences
among cultured confluent and non-confluent bovine aortic endothelial (BAE) cells may
reflect how cells behave in vivo. A study from Brooks et al. (1994) using a monoclonal
antibody antagonist of integrin avP3 selectively induced apoptosis in the proliferating
vascular cells but not in quiescent endothelial cells, which suggested a difference in
apoptosis susceptibility between quiescent and proliferating endothelial cells (Ranta et
al., 1998). There is a need for a better understanding of the different sensitivity between
confluent (quiescent) and non-confluent (replicating) endothelial cells in response to
arsenic. The second specific aim of this study was to determine the different physiology
of confluent and non-confluent cells altered by arsenic toxicity. To our knowledge, it's
the first study on difference of proliferating and quiescent endothelial cells in response to
arsenic.
The vascular system develops through two different processes: vasculogenesis and
angiogenesis. Vasculogenesis is the formation of new blood vessels de novo from
precursor cells, which mainly occurs during embryo development and placenta creation
(Poole et al., 1989). Angiogenesis is the sprouting of new capillaries from pre-existing
blood vessel networks (Coffin et al., 1988). In the adult body, one characteristic of the
vascular network is stability, and angiogenesis is normally absent (Charnock-Jones et al.,
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2004). However, angiogenesis could be activated and occur in certain circumstances,
such as placentation (Gordon et al., 1995). The placenta is very crucial to pregnancy,
providing adequate nourishment and oxygen to the fetus and exchanging wastes from the
fetus. In humans, placental vasculature develops from gestational day 21 to delivery
(Zygmunt et al., 2003) involving both vasculogenesis and angiogenesis processes. The
angiogenesis in human placental vasculature is a complex and 3-dimentional process that
involves sprouting, proliferation and migration of endothelial cells (Charnock-Jones et
al., 2004). In this study, we investigated arsenic toxicity on endothelial cell physiology
that underlies arsenic toxicity on placental angiogenesis.
Knowledge of the cellular and molecular mechanism of arsenic toxicity on
neovascularization in pregnancy is very important for better understanding human
reproductive outcomes during arsenic exposure. Inhibition of endothelial cell apoptosis
and increase of endothelial cell survival in placenta may improve the angiogenesis, thus
helping with vascular development in embryo development.
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CHAPTER 1.

IN VIVO STUDY OF ARSENIC TOXICITY ON

FECUNDITY AND VASCULAR DEVELOPMENT IN MOUSE

INTRODUCTION

Arsenic is an omnipresent metalloid element naturally occurring in the environment in
the earth's crust. It can be released into ground water and soil by both natural processes
and human extractive activity. It also exists in pesticide and wood preservatives,
pigments and glass (Waugh, 1982). Arsenic has organic and inorganic forms. There are
two oxidation-states of inorganic arsenic: Arsenite (As111) and arsenate (Asv). These two
forms speciate in the environment depending upon the level of dissolved oxygen.
However, arsenate can be converted to arsenite in vivo (Abernathy et al., 1999) and it can
be methylated by microbes to MMA (monomethylarsonic acid) and DMA
(dimethylarsinic acid) (Vahter et al., 2001). This process is traditionally regarded as
detoxification pathway because of less acute toxicity of organic arsenic, but a recent
study suggests this may not be the case (Tonner-Navarro, 1998). Sodium arsenite (As111)
was used throughout this project. The main source of human exposure to this toxicant is
contaminated drinking water and some foods, such as rice, grains and fish (ACSH, 2002).
Higher levels of arsenic contamination in drinking water from several hundred ppb to
over 1 ppm have been observed in Argentina, Bangladesh, Chile, India, Mexico, Thailand
and Taiwan (ACSH, 2002). In this country, some states, including Montana, New
Mexico, Arizona, Nevada, Utah, Southern California, Idaho and Nebraska, have 50 ppb-
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100 ppb of arsenic in drinking water; higher than the currently approved 10 ppb MCL
(maximum contaminant level) (ACSH, 2002).
Human epidemiological data suggest an association between arsenic exposure in
drinking water and adverse reproductive outcomes. Basically, they can be concluded into
four main aspects.
1. Spontaneous abortion. In 1989, it was reported that a 1.2-fold increased
spontaneous abortion (95 % confidence interval: 1.0-1.6) was found in a community of
286 women living with low levels of arsenic in drinking water (0.8-1.3 ppb) and a 1.7fold increased spontaneous abortion (95 % confidence interval: 0.7-4.2) was found in a
community with high levels of arsenic (1.4-1.9 ppb) (Aschengrau et al., 1989). A study
from Chile showed that higher incidence of late fetal mortality (rate ration (RR) =1.7;
95% confidence interval (CI), 1.5-1.9), neonatal mortality (RR = 1.52; CI, 1-4- 1.7) and
postneonatal mortality (RR = 1.26, CI, 1.2-1.3) was associated with higher concentration
of arsenic in drinking water (up to 860 ppb) compared to a control community (< 5ppb)
(Hopenhanyn-Rich et al., 2000).
2. Stillbirth. Borzsonyi et al. (1992) reported the potential risk of stillbirth
resulted from arsenic in drinking water in southern Hungary. Another study group in
Bangladesh found the rate of stillbirth (p< 0.046), spontaneous abortion (p< 0.008) and
preterm birth rate (p< 0.018) significantly increased in the arsenic exposed group in
drinking water (>0.1 ppm) comparing with lower level arsenic exposure group (<0.02
ppm) (Ahmad et al., 2001).
3. Preterm birth rate. A report from Taiwan suggested that there was a higher
preterm birth rate (3.74 %) in a group with arsenic exposure in drinking water (from 0.9
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ppb up to 3.59 ppm) vs 3.43 % in a control group (<0.9 ppb) (with an odds ratio of 1.10).
They also found that the babies' birth weight in an exposed group was on average 30 g
(95 % CI= 13.55- 44.55; P=0.002) lighter than those in a control group (Yang et al.,
2003).
4. Birth weight. An epidemiologic study in 2003 from Chile suggested an average
reduction of average birth weight (-57 g; 95% confidence interval = -123 to 9) was
associated with higher level of arsenic in drinking water (42 ppb) compared to control
community (<1 ppb) (Hopenhayn et al., 2003).
These epidemiologic studies were limited by methodological concerns. Human data are
too complicated for interpretation because there are multiple chemicals (copper, barium,
fluoride etc) in drinking water and lifestyle factors could not be excluded. It is also
difficult to determine chronic exposure levels in individuals to correlate the doseresponse effects for arsenic exposure.
There are many experimental animal studies demonstrating arsenic as developmental
toxicant, though the dosages of most of them are intravenous (i.v) or intraperitoneal (i.p)
injection (Holson et al., 2000; Hood, 1978; Hood, 1972). These administration routes
have made it difficult to assess the risk potential of arsenic on human health. Very few
studies have examined the direct toxicity of arsenic exposure in drinking water on
fecundity of pregnant mice, and none of them designed a dose-response study to
determine the lowest concentration of As111 to cause toxicity in developing mice.
Although both these human and experimental studies suggested an association between
arsenic exposures in drinking water with detrimental pregnancy outcomes, it is not clear
why this happens. Both the nutrition and toxicant are transferred to the developing
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embryo through the abundant placental vasculature. Inorganic arsenic of both oxidation
states can easily cross the placenta as a low weight molecule (Desesso et al., 1998;
Dencker 1983; Lindgren 1984). Eastman first discovered that arsenic is accumulated in
human placenta (Eastman, 1931; Desesso et al., 1998). Concha et al. (1998) found that
arsenic in exposed maternal placenta was 34 ng/kg, which was almost 5-fold higher than
control women (7 fig/kg) and most of the arsenic was in DMA (dimethylarsinic acid)
form in the blood plasma of both mother and newborns. In terms of the mechanisms for
fetal and embryonic arsenic toxicity, Hopenhayn et al. (2003) suggested that arsenic
might have vascular effects and cause placental abnormalities or decreased blood flow,
which then retard fetal growth. Further research is needed to provide a better
understanding of the mechanisms for arsenic-induced developmental anomalies.
Based on the current information, we hypothesize that arsenite toxicity impairs vascular
development, causing abnormal placental neovascularization of pregnant mice that
subsequently causes miscarriage. One purpose of this study is to determine how arsenic
exposure affects fecundity, placentation and vascular morphogenesis in pregnant mice.
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MATERIALS AND METHODS

Chemicals Sodium arsenite (Formula: NaAs02, MW: 129.91) was purchased from J. T
Baker (Phillipsburg, NJ), and diluted with deionized distilled water (ddFbO) to yield 0
ppm (0 (xM), 10 ppm (130 |jM), 20 ppm (260 H.M), 37.5 ppm (0.49 mM), 75 ppm (0.98
mM) and 150 ppm (1.9 mM) concentrations of drinking water for mice. It is changed
twice weekly to maintain the desired oxidation states.

Animals FVB/NJ strain mice (7-10 weeks age) were bred from our internal stocks. All
mice were fed a diet of rodent chow (PMI, Brentwood, MO) and tap water ad lib. They
were kept on a 12:12 h light: dark cycle at an environmental temperature of 22 ± 1.5°C,
with a minimum relative humidity of 40 %. For mating, two virgin females were placed
with one stud male and fed with deionized distilled water (ddt^O). The females were
examined daily early morning for semen plug. Detection of a semen plug was designated
day 0.5 (E0.5) of gestation. Pregnant females were placed in separate cages and exposed
to As111 (Sodium Arsenite) through drinking water on a continuous basis throughout
gestational and weaning stage. The control group was kept on ddl-hO.

Data Collection

The number of newborn pups was counted in both the arsenic-treated

group and the control group. The pups were weighed weekly until weaning, when they
were sacrificed. The frequency of delivery after plug was determined by number of
plugged females produced babies divided by total number of plugged females. Prenatal
viability was determined by number of plugged females with embryos alive divided by
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total number of plugged females. Miscarriage rate was determined by number of plugged
females not producing babies divided by total number of plugged females. Miscarriage
rate at E7.5 and E12.5 was determined by number of plugged females not having
embryos divided by total number of plugged females.

Embryo examination

At 7.5 and 12.5 days of gestation (E7.5 and E12.5), pregnant

females were euthanized with carbon dioxide. The uterus was carefully transferred into
sterile PBS and the number of live embryos or plaque resorptions was counted (data not
shown). Live embryos were removed from their surrounding membranes and weighed.
Due to the tiny weight of each embryo, all the live embryos of one litter weighed
together. The mean embryo weight then generated by total weight divided by embryo
numbers each litter. Embryos were stored in 4 % formalin/PBS at room temperature.

BSL-B4 labeling of mouse tissue

After mounting the 4 % formalin-PBS fixed

placentas and embryos in frozen tissue matrix (VWR, Bristol, CT), 10 micron sections
were cut on a Cryostat (England). (Mouse embryos were cut longitudinally). To stain the
endothelial cells in placenta and embryo, fix tissues were soaked in CMPBS (PBS
supplemented with 1 mM CaCh and 1 mM MgCh) 3 times, 5 minutes each. The tissues
were then permeabilized with 100 % methanol for 20 minutes and rehydrated in ethanol
series (95 %-70 %-50 %) for 2 minutes each. After rinsing in CMPBS two times,
Bandeiraea simplicifolia lectin I isolectin B4 (BSL-B4) (Vector Laboratories,
Burlingame, CA) (staining (1, 3)-Gal of endothelial cells) was applied (1 pg/mL in
CMPBS) for 30 minutes at room temperature. After a rinse with CMPBS, Texas Red
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(546) (Molecular Probes, Eugene, OR) was applied at 1:500 for 30 minutes. Following a
final rinse in PBS, the slides were coverslipped with Fluorsave reagent (Calbiochem, San
Diego, CA) and examined with a fluorescence microscope (Nikon Eclipse E600, Japan).
The immunofluorescence staining was analyzed with a Laser scanning cytometer (LSC)
(CompuCyte Corporation, Cambridge, MA). Each datum is an average of three repeated
sections on each slide and 5 different embryo litters (one litter on one slide) in each
group.

Statistical analysis. Results are expressed as the mean ± standard deviation.
Comparisons of means were analyzed by one-way analysis of variance (ANOVA) to
determine intergroup differences. If the results of the ANOVA were significant (p< 0.05),
Tukey's honestly significant difference (HSD) and Dunnett 2-sided test were applied to
the data to compare the treated group with control groups. Frequency of delivery after
plug and prenatal vibility were analyzed by one-way analysis of Chi-square test to
determine at what percentage of confidence the difference between groups were caused
by arsenic exposure in drinking water.
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RESULTS

Dose-response study
To determine how arsenic exposure affected the fecundity of pregnant females, a
preliminary dose-response study was done. Time-pregnant females were exposed to 0, 1,
10, 20, 37.5, 75 or 150 ppm arsenic in drinking water on a continuous basis of gestational
and weaning stages. The number of pups from each mother and average pup weight per
litter at postnatal week 1, 2 and 3 was calculated (Table 1). There were strikingly
increased miscarriage rates at 20 ppm (52.6 %), 37.5 ppm (61 %) and 75 ppm (69.7 %) vs
control (28 %) (Table 2, Figure 1A). P value (<0.01) (Table 2) showed there is absolute
dependence between the changing in miscarriage rate and the changing in arsenic
exposure for these plugged mice. Although the pup number per litter in the arsenic
treated group tended to be lower with increasing arsenic concentrations (from 1 ppm to
37.5 ppm) compared to controls (Table 1, Figure IB), this finding was not statistically
significant. We didn't see any significant difference in mean pup weight per litter in each
arsenic treated group compared to control group either (Table 1, Figure 1C). To minimize
the effects of maternal toxicity (The group treated with 150 ppm arsenic died 2-4 weeks
after exposure.), the concentration of arsenic in drinking water used in subsequent
experiments was focused on 20 and 37.5 ppm.

Embryogenesis
Effects of arsenic on developmental competence of embryos were examined at E7.5
and E12.5 stages. The miscarriage rate for 20 ppm stayed the same at E7.5 and E12.5.
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However, the miscarriage rate in 37.5 ppm arsenic group dramatically increased from 43
% at E7.5 to 60 % at E12.5 (Table 3, 4, Figure 3A, Figure 4A). There was a clear doseresponse decrease of prenatal viability at El 2.5 (Table 4, Figure 3A). However, the Pvalue from chi-square test showed that miscarriage rates in 10 ppm, 20 ppm and 37.5
ppm groups at El 2.5 stage are independent of arsenic exposure in drinking water (Table
4). The same results were obtained at E7.5 stage (Table 3). Embryo number for each litter
at El2.5 had a dose-related decrease (Table 4, Figure 3B), although the difference was
not statistically significant. In contrast, we did not observe any decrease of embryo
number of each litter mentioned above at E7.5 stage (Table 3, Figure 2B). We didn't
observe any significant difference of mean pup weight in the various arsenic
concentration groups comparing to control group at E7.5 or El2.5 (Table 3, Table 4,
Figure 2C, Figure 3C). Figure 4 shows a summary of arsenic toxicity and its effects on
pregnancy and embryonic development. The data show trend toward smaller litters at
both the E12.5 and birth stages. The data also show trend toward lower birth weight with
increasing arsenic toxicity at El 2.5. The most significant result is loss of the entire litter
(P < 0.01), i.e. complete miscarriage, resulting from arsenic toxicity.

Vasculature
Placentas and embryos were examined for morphological variance and for vascular
abnormalities. The insert micrograph (Figure 5E) shows three representative placentas
from As"1 treated (top) and control (bottom) E12.5 females. The placentas of 37.5 ppm
arsenic treated group were darker than those of control group may suggest a hemorrhage
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and oxidation of hemoglobin. The enlargement of arsenic treated placentas may suggest a
hypertrophy due to abnormal vasculogenesis (Figure 5E).
Fixed placentas and embryos were stained with Bandeiraea simplicifolia lectin I
isolectin B4 (BSL-B4) (staining (1, 3)-Gal of endothelial cells) and fluorescence was
quantified with the laser scanning cytometer (LSC). There were numerous large cavities
in the tissues and more loosening of cell connections in arsenic treated placenta (Figure
5B) and embryo (Figure 5D) compared to control placenta (Figure 5A) and embryo
(Figure 5C), which showed dramatic tissue damage. Quantification of fluorescence
showed significantly loss of BSL-B4 positive staining (p<0.05) in placenta from 37.5
ppm As111 treated group (51.99 %) at E12.5 versus the control group (100 %) (Figure 5E).
The embryonic vasculature of this group decreased to about 65.69 % compared to control
(100 %), though not statistically significant (Figure 5E). In contrast, the BSL-B4 labeling
in 20 ppm arsenic treated placenta (122.09 %) didn't have any statistically significant
difference compared to control placenta (100 %), nor did the BSL-B4 labeling in 20 ppm
arsenic treated embryos (65.55 %) compared to control embryos (Figure 5E).
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Table 1. Summary of arsenic effects on fecundity of pregnant mice

Numbers of plugged females with
pups (n)
Pups per litter (n) (mean ± SD)
Mean pup Weight (g) Week 1
(Mean ± SD)
Week 2
Week 3

Control

1ppm

10ppm

20ppm

37.5ppm

75ppm

12
9±4
4 15 ±0.62
6.6 ± 1.50

11
7.91 ±2.98
4.60 ±0.68
7.25 ± 1.41

9
7.44 ±3.13
4 78 ± 0.85
7.94 ± 1.55

9
6.89 ± 2.47
4.73 ± 1.31
7.35 ± 1.58

10
5.55 ± 2.66
4.29 ± 0.56
7.78 ± 1.32

10
7.1 ±1.73
3.65 ± 0.5
5.43 ±0.7

9.88 ±2.73 10.99 ±2.07 11.48 ±2.14 10.88 ± 1.97 11.36 ± 1.56 8.17± 1.5
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Table 2. Miscarriage rate for birth

Number of plugged females with pups (n)
Number of plugged females without pups (n)
Frequency of delivery after plug
Miscarriage rate
P-value (Chi-square test)

Control

1ppm 10ppm

20ppm

37.5ppm 75ppm

13
5
72%
28%
P< 0.01

11
4
73%
27%

9
10
47.4%
52.6%

11
17
39%
61%
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Figure 1. Dose-response relationship for arsenic toxicity on fecundity of pregnant mice.
Plugged mice were exposed to various concentration of arsenic throughout all the
gestational and weaning stages. Litters were counted and pups were weighted weekly. A.
Calculated frequency of delivery after plug. B. Number of pups per litter. C. Mean pup
weight per litter at week 1, 2 and 3 postnatal. Error bars represent the mean +/- SD for
n>9 each group.
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Table 3- Effects of arsenic toxicity on E7.5 embryo development
Numbers of plugged females with embryos (n)
Embryos per litter (n) (mean ± SEM)
Mean embryo weight (g) (mean ± SEM)
Numbers of plugged females without embryos (n)
Prenatal viability
Miscarriage rate (%)
P-value (Chi-square test)

ns: not significant
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Control
10
7.9 ± 2.92
0.0141 ±0.0054
5
67%
33%
ns

37.5ppm
20ppm
10
8
8.8 ± 1.99
8.38 ±3.81
0.0146 ± 0.0018 0.0139 ± 0.001
9
6
57%
53%
43%
48%
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Figure 2. Effect of arsenic toxicity on embryo development at E7.5. Plugged mice were
exposed to various concentration of arsenic from E0.5 to E7.5. Live embryos were
counted and weighed. A. Prenatal viability at E7.5. B. Numbers of embryo per litter at
E7.5. C. Mean embryo weight per litter at E7.5. Error bars represent the mean +/- SD for
n>8 each group.
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Table 4. Effects of arsenic toxicity on E12.5 embryo development
Control
Numbers of plugged females with embryos (n)
10
Embryos per litter (n) (mean ± SEM)
8.9 ± 2.85
Mean embryo weight (g) (mean ± SEM)
0.0965 ± 0.040
Numbers of plugged females without embryos (n) 2
Prenatal viability
83%
Miscarriage rate (%)
18%
P-value (Chi-square test)
ns

ns: not significant
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10ppm
7
8.86 ± 2.97
0.0779 ±0.016
2
77%
23%

20ppm
8
8.38 ± 2.77
0.0828 ±0.020
7
53%
50%

37.5ppm
6
6.83 ± 2.5
0.076 ± 0.
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Figure 3- Effect of arsenic toxicity on embryo development at El2.5. Plugged mice were
exposed to various concentrations of arsenic from E0.5 to E12.5. Live embryos were
counted and weighed. A. Prenatal viability at El 2.5. B. Numbers of embryo per litter at
E12.5- C. Mean embryo weight per litter at E12.5. Error bars represent the mean +/- SD
for n> 6 each group.

23

S Control

<d

& >

• 20ppm

W ±1

• 37.5ppm

O£ 5
(0

70%
60%
50%

•S
2
«4— (0
o c

40%

> L

30%

e £

20%
10%

I<D fQ.

0%

1 m
E7.5

11. .11 i 11: .11
E12.5

Birth

14

B

= 12

a0)

8 10
t
I 8
O
U)
a

11

3

a

0 Control

ill

4 -

II

• 20 ppm

•

El 37.5 ppm

no
E
3

z

E12.5

E7.5

Birth

c
0 Control

| 0.16

ED 20ppm

Ui
r o.i4
a>

37.5ppm

1 0.12

8. 0.1 -|
O) 0.08
"a>

5 0.06

0

£ 0.04

1 0.02
£

03

<d

0

Hi
E7.5

E12.5

Figure 4. Summary of arsenic toxicity on fecundity of pregnant mice and embryo
development at E7.5 and E12.5 stages. Error bars represent the mean +/- SD for n> 6
each group.

24

E

160.00%
o

140.00%

§ 120.00%

o

° 100.00%

m

c

m control
• 20ppm

80.00%

®37.5ppm

|
TO 60.00%
CDI
£0

4000%

m

20.00%
0.00%

Placenta

Embryo

Figure 5. Examination of vasculature of placenta and embryo at El 2.5. Pregnant mice
were exposed to 0, 20 and 37.5 ppm arsenic from E0.5 till E12.5. Placentas and embryos
were stained with BSL-B4 and quantified with LSC. (A) Control placenta. (B) 37.5 ppm
arsenic exposed placenta. (C) Control embryo. (D) 37.5 ppm arsenic exposed embryo.
(A-D) 20x magnification. (E) Amount of endothelial cells in placentas and embryos at
E12.5. The amount of endothelial cells is expressed as percentage of control. Error bars
represent the mean +/- SD for n=5 each group. Inset shows photographs of placentas
before staining (lx magnification). 37.5 ppm arsenic exposed placentas in upper level.
Control placentas in lower level.

DISCUSSION

Arsenic exposure through drinking water from E0.5 through weaning causes defects in
placentation and lower fecundity in pregnant females. Drinking water exposure to sodium
arsenite did not cause a statistically significant difference in the litter size at any time
point. Our study suggests that primary effect of arsenic on pregnant mice was a dosedependent increase in conceptus mortality (miscarriage rate). Previous studies reported
that embryonic malformations resulted from arsenic exposure by intraperitoneal (i.p.) or
intravenous (i.v.) routes of pregnant mice (Hood, 1972; Morrissey, 1983). In this study,
we didn't observe any obvious offspring malformations, which is consistent with the
research results of Stump et al. (1999) that oral administration of arsenic in rats by
gavage only resulted in increased prenatal mortality. We also didn't see any other adverse
pregnancy outcomes, such as preterm delivery. All the pregnant females delivered at 1921 gestational days without any observable increase in stillbirth. We did not observe any
obvious increase of the resorptions plaques atE12.5in37.5 ppm arsenic treated group
compared to control group. To our knowledge, this is the first study associating arsenic
exposure in drinking water with lower fecundity of pregnant females. However, the
results of this study should be considered within the context of limitations in the study
design. In our study, we didn't have exposure assessment and the consumption of arsenic
water may vary between groups.
In this study, we examined the E7.5 and El2.5 stages to monitor vascular development
from when it is first evident to functionally accomplished. Comparison of E7.5 to
neonatal stage miscarriage rates shows that the spontaneous abortion mostly happened in
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postimplantation stage between E7.5 to El 2.5 stage. Examination of the placenta and
embryonic vasculature showed arsenic toxicity impairs placental vascular development,
which probably predisposes the embryo to miscarriage. In the 20 ppm arsenic treatment
group, the miscarriage rate stayed almost the same from E7.5 (47 %), E12.5 (47 %) to
birth (52 %). In contrast, the miscarriage rate for the 37.5 ppm arsenic treatment group
increased from 43 % at E7.5 to 60 % at E12.5, which is within error, the same as the 61
% rate at birth. These data suggest that the mechanisms for miscarriage caused by arsenic
exposure at 20 ppm may be different from the mechanisms at 37.5 ppm. However, the
reason for this difference is not clear. The high miscarriage rates at E7.5 (47 %) and
E12.5 (43 %) may suggest that the pre-implantation stage is also an important stage for
arsenic toxicity. The data for 20 ppm may suggest that pre-implantation is a critical time
for arsenic toxicity related spontaneous abortion; versus 37.5 ppm treatments where the
mechanism of arsenic toxicity may have two stages: pre-implantation and placental
neovascularization during post-implantation. In 2002, Krininger et al. demonstrated that
arsenic could impair the pre-implantation development of bovine embryos. They showed
that apoptosis and group 2 caspase activity were increased after exposure to arsenic at E5
(embryos >16 cells in number) and the cell number was reduced after exposure to
arsenic at El.5 (two-cell stage). They also found that the percentage of embryos that
developed to the blastocyst stage was reduced by arsenic exposure at both El .5 and E5
(Krininger et al., 2002). The magnitude of increasing miscarriage rate at postimplantation stage was less than that at pre-implantation stage, which is consistent with
the report that developmental toxicity of inorganic arsenic was gestational age
dependence (Tabacova et al., 1996). With increasing gestational age there was an

28

increasing resistance to arsenic-induced effects. In 1981, Harrison and Hood reported that
exposure to arsenate by hamsters on E9 caused complete resorptions of all implantation
sites while the same dose on El 1 and El2 only resulted in weight reduction (Harrison
and Hood, 1981; Tabacova et al., 1996). However, current study indicates that another
possibility is maternal oxidative stress induced by arsenic followed by abnormal placental
neovascularization that is likely to make embryo more susceptible to arsenic toxicity. We
found that the placentas and embryos in the arsenic treated group contained vascular
morphological anomalies. These results are consistent with reports of cavernous damage
to both endodermal epithelium and mesodermal mesothelium in arsenic treated mouse
embryo and yolk sac placenta (Li et al., 1997). Likewise, we found decreased quantities
of endothelial cells in the El 2.5 placenta of pregnant mice treated with 37.5 ppm (0.49
mM) sodium arsenic in drinking water; which is consistent with the finding of Soucy NV
et al. (2003) that concentration of arsenic greater than 1 |xM inhibits vessel growth in vivo
in a chicken chorioallantoicmemebrane (CAM) assay. They also found that the threshold
As111 concentration for this transition from stimulation to inhibition of vessel density is
. In summary, our study shows the development of embryo highly dependents

0.033 |jM

on a functional placenta and functional disturbance of placenta could heavily impair
embryo development.
In this study, the different miscarriage rates for the control groups in the different
experiments (Figure 4A) are likely to due to normal variance. Perhaps weighing the
females before the experiments would have reduced the variance, though all of them were
between 7 to 10 weeks age.
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CHAPTER 2. A Comparison of Arsenic Toxicity on Viability, Proliferation and
Apoptosis of Proliferating and Non-proliferating Bovine Aortic Endothelial Cells

INTRODUCTION

Endothelial cells are the innermost lining of blood vessels that form the vascular
network. They are the major places where nutrients and toxicants enter the blood vessel.
They are also the frontier targets of toxicants on vascular networks, and the function of
endothelial cells is the foundation of a functional and homeostatic vasculature. The
balance between endothelial cell proliferation and apoptosis, resulting in the viability of
endothelial cells, directly controls vascular differentiation and angiogenesis. We
hypothesize that arsenite toxicity impairs vascular development causing an inadequate
perfusion of tissues that subsequently causes miscarriage. To better understand the
toxicity of arsenic on the vasculature, it is very important to study the effect of arsenic on
endothelial cells. In embryonic life, endothelial cells actively proliferate and differentiate.
The apoptosis of endothelial cells can severely destroy vasculogenesis in embryo
development and placenta and cord development, leading to serious hemorrhage, finally
causing embryo death (Dimmeler et al., 2000). In contrast, in adult life endothelial cells
are typically quiescent and turn over slowly, similar to the situation for confluent cells in
culture. The apoptosis of endothelial cells in adult neovasculature can regulate the adult
angiogenesis to avoid excess angiogenesis (Dimmeler et al., 2000). The differences
among cultured confluent and non-confluent bovine aortic endothelial (BAE) cells may
reflect how cells behave in vivo. A study from Brooks et al. (1994) using a monoclonal
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antibody antagonist of integrin 0^3 selectively induced apoptosis in the proliferating
vascular cells but not in quiescent endothelial cells, which suggested a difference in
apoptosis susceptibility between quiescent and proliferating endothelial cells (Ranta et
al., 1998). There is a need for a better understanding of the different sensitivity between
confluent (quiescent) and non-confluent (replicating) endothelial cells in response to
arsenic. The second specific aim of this study was to determine the different physiology
of confluent and non-confluent cells altered by arsenic toxicity. To our knowledge, it's
the first study on difference of proliferating and quiescent endothelial cells in response to
arsenic.
The vascular system develops through two different processes: vasculogenesis and
angiogenesis. Vasculogenesis is the formation of new blood vessels de novo from
precursor cells, which mainly occurs during embryo development and placenta creation
(Poole et al., 1989). Angiogenesis is the sprouting of new capillaries from pre-existing
blood vessel networks (Coffin et al., 1988). In the adult body, one characteristic of the
vascular network is stability, and angiogenesis is normally absent (Charnock-Jones et al,
2004). However, angiogenesis could be activated and occur in certain circumstances,
such as placentation (Gordon et al., 1995). The placenta is very crucial to pregnancy,
providing adequate nourishment and oxygen to the fetus and exchanging wastes from the
fetus. In humans, placental vasculature develops from gestational day 21 to delivery
(Zygmunt et al., 2003) involving both vasculogenesis and angiogenesis processes. The
angiogenesis in human placental vasculature is a complex and 3-dimentional process that
involves sprouting, proliferation and migration of endothelial cells (Charnock-Jones et
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al., 2004). In this study, we investigated arsenic toxicity on endothelial cell physiology
that underlies arsenic toxicity on placental angiogenesis.
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MATERIAL AND METHODS

Chemicals Sodium arsenite (Formula: NaAs02, MW: 129.91) was purchased from J. T
Baker (Phillipsburg, NJ), and diluted with sterile PBS to yield arsenic concentrations of
0, 1,5, 10, 20 and 50 |xM to treat BAE cells.

Cell Culture

Bovine aortic endothelial (BAE) cells were cultured in Dulbecco's

modification of eagle's medium (DMEM) (Gibco, Grand Island, NY) supplemented with
1 % penicillin-streptomycin-glutamine (PSG) (Hyclone Laboratores, Logan, Utah) and
15 % fetal bovine serum (FBS) (Hyclone Laboratores, Logan, Utah). The cells were
incubated at 37 °C in a humidified atmosphere of 5% CO2. The cells were harvested with
0.05 % Trypsin-EDTA (Gibco, Grand Island, NY) and only passage between 2-6 were
used. Cells reached confluence on 96 well plates and chamber slides two days after
passage. One day post-confluent was used for all confluent cells. The culture medium for
confluent cells was changed to fresh medium 18-24 hours before being treated with
arsenic. Cells grown for one day (24 h) post-passage were considered non-confluent. Cell
density was assayed with a Coulter Particle Counter (Beckman Coulter Corporation,
Miami, FL).

Cell viability assay

Cell viability was determine with the modified MTT assay

(Bunderson, et. al., 2002). Cells were seeded in 96 well plates at 1.5 x 105 cells/ml.
Sodium arsenite solutions were applied for 24 hours. MTT (50 jig) (Sigma, St. Louis,
MO) was added to each well and cells were incubated for four hours. Medium/MTT
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solutions were removed and 100 fxL DMSO was added to dissolve the MTT formazan
crystals. Absorbance was measured with Spectra Max 340 (Molecular Device,
Sunnyvale, CA) at 550 nm.

Cell proliferation assay

BAE cells were seeded in 96 well plates at 1.5 x 105 cells/ml.

After being treated with arsenic for 24 hours, a cell proliferation assay was performed
with the use of BrdU (bromodeoxyuridine) Cell Proliferation Assay Kit (Oncogene,
Cambridge, MA), according to the manufacturer's instructions. Absorbance was
determined with Spectra Max 340 at dual wavelengths of 450-540 nm.

TUNEL assay BAE cells were grown to confluence or non-confluence on 2% (w/v)
gelatin (Sigma, St. Louis, MO) (diluted with PBS) coated Lab-Tek II Chamber slides
(Nalge Nunc International, Naperville, IL) and incubated with arsenic concentrations of
0, 1,5, 10, 20 or 50 ftM for 24 hours. A TUNEL (terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling) assay was performed with the use
of ApoAlert DNA Fragmentation Assay Kit (Clontech, Palo Alto, CA) according to the
manufacturer's instructions. Propidium iodide used in this assay was purchased from
Sigma (St. Louis, MO). Fluorescence was quantified with a Laser Scanning Cytometer
(LSC; CompuCyte Corporation, Cambridge, MA).

Statistical analysis. Results are expressed as mean ± standard deviation. Comparisons of
means were analyzed by one-way analysis of variance (ANOVA) to determine intergroup
differences. If the results of the ANOVA were significant (p<0.05), Tukey's honest
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significant difference (HSD) and Dunnett 2-sided test were applied to the data to compare
the treated and control groups.
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RESULTS

Cell Viability assay
Confluent and non-confluent BAE cells were grown in 96-well plates (1.5 x 105
cells/ml) and a dose-response relationship to 24 hours of arsenic toxicity was determined
with a MTT assay. There were dose-dependent decreases in viability after arsenic
exposure in both confluent and non-confluent cells. In non-confluent cells, there was a
significant decrease in viability from 5 |xM to 50 |xM compared to controls (Figure 6a),
whereas confluent cells revealed a significant decrease in viability at arsenic
concentration of 20 [aM and 50 jxM only (Figure 6b). However, at 50 |j.M arsenic
exposure, the confluent cells had a significantly decreased cell viability compared to non
confluent cells (Figure 6c), which may suggest confluent BAE cells are more susceptible
to arsenic toxicity.

Cell Proliferation assay
Confluent and non-confluent BAE cells were grown in 96-well plates and a doseresponse study of cell proliferation was determined with the BrdU Proliferation Assay.
Significant decreases in cell proliferation were found in proliferating (non-confluent)
cells from 5 jxM to 50 jxM compared to control (Figure 7a); in contrast there was only a
significant difference at highest concentration (50 |j,M) in confluent cells (Figure 7b). The
non-confluent control BAE cells showed significantly more proliferation than confluent
control cells. However, they only had significant difference at control and 1 |xM point and
lost this difference at more than 1 ^M concentrations. This suggests that non-confluent
BAE cells have more susceptibility to proliferation loss as a result of arsenic toxicity.
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TUNEL assay for apoptosis
Confluent and non-confluent BAE cells were seeded in gelatin coated chamber slides
and a dose-response study of cell apoptosis to 24 hours arsenic toxicity was conducted
with a TUNEL assay. There was a significant increase in BAE apoptosis in both
confluent and non-confluent cells at 1, 10, 20 and 50 |jM sodium arsenite (Figure 8a, b).
There was no significant difference between the two groups at any dose point (Figure 8c),
though there was a trend of higher percentage of apoptosis cells in confluent BAE cells
vs non-confluent cells.
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Figure 6. Cell viability for confluent and non-confluent BAE cells treated with various
concentration of sodium arsenite (As111) for 24 h. Viability was measured using an
adaptation of MTT colorimetric assay as described under Methods. Viability is expressed
as percentage of control (untreated cells); Error bars represent mean +/- SD for n=4.
There is significant difference at all concentration point between confluent and non
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Figure 7. Cell proliferation for confluent and non-confluent BAE cells treated with
various concentration of sodium arsenite (As111) for 24h. Cell proliferation was measured
using BrdU cell proliferation assay (Oncogene, Cambridge, MA). There is significant
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concentration of sodium arsenite (As111) for 24h. Cell apoptosis was measured using
ApoAlert DNA fragmentation assay (Clontech, Palo Alto, CA). Apoptosis is expressed as
percentage of control (untreated cells); error bars represent mean +/- SD for n=4.
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DISCUSSION

Our data showing a dose-dependent decrease of cell proliferation in proliferating (non
confluent) cells in response to arsenic treatment and a significant decrease starting from 5
fiM are consistent with the decreased thymidine incorporation observed by others in
exponentially growing porcine aortic endothelial cells (Barchowsky et al., 1996). This
shows that the proliferation of non-confluent cells is not stimulated by arsenic at low
concentration. In contrast, we observed a small trend of increasing cell proliferation from
1 |xM to 5 fiM sodium arsenite in confluent cells (though not significant), which is
consistent with the previous report that low concentration of arsenic has a mitogenic
effect on postconfluent endothelial cells (Barchowsky, 1996).
There was significant loss of cell viability of endothelial cells from 5 |xM in both
confluent and non-confluent BAE cells in this study. This is consistent with previous
findings that concentrations greater than 5 jxM are toxic to endothelial cells (Barchowsky,
1996; Deneke, 1992). From the data, we found proliferating cells (non-confluent) had
higher cell viability after exposure to 50 |nM arsenic for 24 than that of quiescent
(confluent) cells, which may suggest a greater sensitivity of quiescent cells to arsenic
toxicity.
From the TUNEL assay, we did not observe any significant difference of increased
apoptosis in response to arsenic treatment between confluent and non-confluent situation.
There was only a trend of more apoptosis in quiescent BAE cells than proliferating cells,
which may suggest the more sensitivity of quiescent cells vs proliferating cells to arsenic
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toxicity which is consistent with the study from Queille et al. (2001) that growing cells
had lower rates of apoptosis from UV damage than confluent cells.
However, we observed significant increase of cell apoptosis in both confluent and non
confluent situation compared to each control after 24 h treatment with 1 (xM arsenic and
lost this significant difference at 5 fiM concentration followed by significant increase of
apoptosis again. This is consistent with the study results from Barchowsky that there was
no sign of cell death in primary porcine aortic endothelial cells exposure to 5 |xM
arsenite, even following exposure for 96 hours (Barchowsky et al., 1999). They also
reported a significant cell loss after 48 h with concentrations greater than 10 |xM, which
agrees with the results showing here. In the other hand, low concentration of arsenic
exposure (< 1 |uM) stimulates angiogenesis in vitro (Kao et al., 2003). Another study
from Barchowsky et al (1996) demonstrated that oxidant generation (dichlorofluorescin
(DCF)) peaked at 5 jxM sodium arsenite in porcine endothelial cells and decreased to
basal line starting from 10 |xM arsenite. They also suggested that this increased
intracellular oxidant formation promote nuclear translocation of trans-acting factors (NFKB) and therefore be mitogenic to endothelial cells growth. One implication from these
literatures and the data of current study is that 1 |j,M - 5 jxM - 10 jxM may be a transit
window of arsenic effects from stimulation angiogenesis to inhibition angiogenesis. The
possible explanation for the phenomena we observed in TUNEL assay is that arsenic
stimulates the apoptosis at 1 fiM, which is then compensated by the mitogenic effect of
arsenic at 5 jxM and finally gets to inhibitory effect again at 10 fiM.
At 50 jxM arsenic concentration, we observed a significantly less viability of confluent
cells compared to non-confluent cells. In contrast, we didn't see any significant
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difference of cell apoptosis or proliferation between confluent and non-confluent BAE
cells. One of the reasons for that may be most of confluent cells are undergoing necrotic
cell death instead of apoptosis. Previous research showed that bovine embryos can
acquire increased resistance to certain cellular stress (cyanide toxicity) as they advance in
development (Donnay et al., 2000). Like the actively proliferating cells in embryo, we
can speculate that the surviving proliferating BAE cells may also gain a better resistance
to exogenous toxicant (arsenic) than quiescent cells do.
In conclusion, there was a dose-dependent inhibition of both cell proliferation and
viability, and an increase in apoptosis by arsenic treatment for 24 hours on both confluent
and non-confluent BAE cells.
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CONCLUSIONS

The major findings of this project were: Decreased fecundity in As111 exposed pregnant
female mice due to vascular defects in the placenta (Chapter 1) and As111 mediated
endothelial cell death (Chapter 2). Results from in vitro arsenic exposure experiments
with BAE cells suggest that the defects in vascular development could result from a loss
of endothelial cell viability; particularly in the placenta. The decline in the viability could
result from lower proliferation, increased apoptosis, or a combination of both factors
(Chapter 2). In conclusion, this study suggests As111 induced apoptosis and/or inhibition of
proliferation in the developing placental endothelium may be the cause of the increased
miscarriages in As111 exposed pregnant female mice.
Future studies will address this hypothesis. Both the proliferation and apoptosis of
endothelial cells will be assayed on placenta from As111 exposed mice. Currently, the
mechanism of the regulation of angiogenesis in the placenta is not particularly well
understood. Some endothelial growth factors, particularly vascular endothelial growth
factor (VEGF), play very important roles in the process of vascular development. These
growth factors may be the targets of an exogenous toxicant, resulting in vascular defects.
It would also be interesting to study the differential expression of these proteins in
placenta in response to arsenic toxicity in future research.
Arsenic readily reacts with thiol-containing molecules such as GSH and cysteine,
which are critical in biochemical reactions, leading to toxicity (Scott et al., 1993).
However, the mechanism of arsenic toxicity in molecular level is still not very clear.
Some studies suggested arsenic genotoxicity, such as chromosomal aberrations, DNA-
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protein crosslinks, and sister chromatid exchanges in hamster embryo cells after arsenic
exposure (Rossman et al., 1980; Lee at al., 1985, Kochhar et al., 1996). Arsenic also
alters DNA repair in human T-cell lymphoma cells by decreasing repair enzyme poly(ADP-ribose) polymerase at 10 fiM concentration, therefore causing decreased cell
viability (Yager and Wiencke, 1997). Arsenic is also reported to cause some of the
detrimental actions on cells by increasing superoxide anion generation (O2 ) and lipid
peroxidation, which correlated with increased apoptosis of human gastric cancer cells
(Chen et al., 2002). The reports referenced here and the results of this study clearly show
that exposure to arsenic alters endothelial cell physiology. Does that alteration of
endothelial cell physiology reach the threshold of pathological endothelial cell
dysfunction? Collectively: The cardiovascular pathologies associated with arsenic
toxicity in humans, in vitro studies exposing cultured endothelial cells to arsenic, and in
vivo arsenic toxicity experiments such as this one all show that arsenic exposure causes
endothelial dysfunction.
Lee et al. demonstrated that arsenic increased the susceptibility of platelets to
aggregate, leading to the increased risk of arterial thrombosis, which is a causal factor in
the development of cardiovascular disease (Lee et al., 2002). This study and the results
presented here strongly suggest that arsenic related endothelial cell dysfunction is directly
linked to cardiovascular disease and developmental disorders. The necessary arsenic
exposure levels and the nature of the endothelial cells dysfunction are clearly different in
a tissue specific manner. For example, arsenic exposure to atherosclerotic mice results in
endothelial dysfunction that accelerates atherogenesis (Bunderson et al., 2002).
Conversely, this report shows that arsenic exposure to the developing embryo results in
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endothelial dysfunction manifest as placental insufficiency that result in miscarriage.
Future studies for this project will focus on endothelial cell dysfunction in the context of
development. Particularly how arsenic mediated endothelial dysfunction affects
angiogenesis and vasculogenesis, the two fundamental mechanisms for vascular
development (Coffin and Poole, 1988).
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